Related Experiment Video

Updated: Jun 30, 2026

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

[Chronic systolic heart failure - dosing recommendations at beginning and end of treatment]

Christian Zugck1, Andrew Remppis, Hugo A Katus

  • 1Abteilung für Innere Medizin III, Universitätsklinikum Heidelberg. Christian_Zugck@med.uni-heidelberg.de

Therapeutische Umschau. Revue Therapeutique
|September 30, 2008
PubMed

Insights

Managing chronic heart failure involves complex therapies. This paper details medical strategies, focusing on when to start and stop medications for systolic dysfunction to improve patient outcomes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Context:

  • Chronic heart failure (CHF) is a complex, multi-system disease requiring intricate, multimodal therapeutic approaches.
  • Optimizing guideline adherence in advanced CHF presents significant clinical challenges.
  • Recent reductions in CHF morbidity and mortality are strongly linked to diligent implementation of evidence-based treatment targets.

Purpose:

  • To provide a comprehensive overview of medical therapeutic strategies for chronic systolic dysfunction.
  • To specifically address the critical aspects of drug initiation and discontinuation in managing CHF.
  • To guide clinicians in optimizing pharmacotherapy for patients with chronic systolic dysfunction.

Summary:

  • This review synthesizes current medical therapeutic strategies for chronic systolic dysfunction.
  • It emphasizes the importance of precise drug initiation and discontinuation protocols.
  • The focus is on enhancing guideline adherence for improved patient management.

Impact:

  • Facilitates better understanding and implementation of guideline-directed medical therapy in CHF.
  • Aims to reduce morbidity and mortality by optimizing drug management strategies.
  • Supports clinicians in making informed decisions regarding pharmacotherapy for chronic systolic dysfunction.

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...